# reload+after+2024-01-23 15:45:53.947999
address1§345 Park Avenue South
address2§6th Floor
city§New York
state§NY
zip§10010
country§United States
phone§212-547-9879
website§https://www.lexeotx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. R. Nolan Townsend', 'age': 43, 'title': 'CEO & Director', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 705432, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Paul B. McCormac Ph.D.', 'age': 53, 'title': 'Chief Technical Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 471729, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jenny R. Robertson', 'age': 49, 'title': 'Chief Legal & Administrative Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 436126, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ronald G. Crystal M.D.', 'title': 'Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric  Adler M.D.', 'age': 50, 'title': 'Chief Scientific Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Micah  Zajic', 'age': 42, 'title': 'Chief Business Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jordan  Shin M.D., Ph.D.', 'title': 'Senior Vice President of Clinical Development & Translational Science, Cardiology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jordan S. Dubow M.D.', 'age': 45, 'title': 'Head of CNS Clinical Development', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sandi See Tai M.D.', 'title': 'Senior Vice President of Clinical Development & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ryan  McHenry', 'title': 'VP & Corporate Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
priceToSalesTrailing12Months§Infinity
currency§USD
dateShortInterest§1702598400
forwardEps§-2.73
exchange§NGM
quoteType§EQUITY
shortName§Lexeo Therapeutics, Inc.
longName§Lexeo Therapeutics, Inc.
firstTradeDateEpochUtc§1699018200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ab1fdece-ecd1-3551-bd81-6134d29606b5
gmtOffSetMilliseconds§-18000000
targetHighPrice§23.0
targetLowPrice§19.0
targetMeanPrice§20.8
targetMedianPrice§20.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§1.539
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
